Publications

1. GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

   Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

   Report | 14-06-2021

2. GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome

   The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V. Osilodrostat ...

   Report | 14-06-2021

3. GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

   The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a ...

   Report | 08-06-2021

4. GVS advice Vocabria® and Rekambys® for the treatment of HIV-1 infection

   The National Health Care Institute has completed its assessment whether the products Rekambys® and Vocabria® can be included in ...

   Report | 08-06-2021

5. Package advice isatuximab (Sarclisa®) for the treatment of multiple myeloma

   The National Health Care Institute has completed its assessment whether isatuximab (Sarclisa®) in combination with carfilzomib ...

   Report | 25-05-2021

6. GVS advice ivacaftor (Kalydeco®) extension of further conditions

   Zorginstituut Nederland carried out a review to extend the further conditions for reimbursement of ivacaftor (Kalydeco®). The ...

   Report | 25-05-2021

7. GVS advice dapagliflozin (Forxiga®) extension of further condition

   The National Health Care Institute has completed its assessment whether the further condition of dapagliflozin (Forxiga®) could ...

   Report | 12-05-2021

8. Package advice pertuzumab and trastuzumab (Phesgo®) for the treatment of breast cancer

   Zorginstituut Nederland has completed its assessment whether the fixed combined dose of pertuzumab and trastuzumab (Phesgo®) can ...

   Report | 11-05-2021

9. Package advice onasemnogene abeparvovec (Zolgensma®) for the treatment of SMA

   Zorginstituut Nederland has completed its assessment whether onasemnogene abeparvovec (Zolgensma®) for the treatment of patients ...

   Report | 06-05-2021

10. GVS advice inclisiran (Leqvio®) for the treatment of hypercholesterolemia

    The National Health Care Institute has completed its assessment whether inclisiran (Leqvio®) is interchangeable with a product ...

    Report | 04-05-2021